|Videos|October 8, 2021
New Data Surrounding Pediatric Pneumococcal Disease Shows Promise
Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.
Advertisement
Pharmacy Times spoke with Luwy Musey, executive director in biologics and vaccines clinical research at Merck, about the results from two phase 3 pediatric studies surrounding pneumococcal disease that was presented at the IDWeek 2021 conference.
Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
2
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
3
Online GLP-1 Sellers Often Skip Clinician Oversight, Secret Shopper Study Finds
4
Emavusertib-Based Therapy Produces Responses in BTK Inhibitor–Treated Primary CNS Lymphoma
5